

---

**Neuland Laboratories Limited**

Sanali Info Park, 'A' Block,  
Ground Floor, 8-2-120/113  
Road No. 2, Banjara Hills  
Hyderabad - 500 034.  
Telangana, India.

Tel: 040 30211600 / 23551081

Fax: 040 30211602

Email: [neuland@neulandlabs.com](mailto:neuland@neulandlabs.com)

[www.neulandlabs.com](http://www.neulandlabs.com)

---

February 12, 2020

To  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai - 400 001

To  
**The National Stock Exchange of India Ltd**  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai - 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANDLAB; Series: EQ**

Dear Sirs,

**Sub: Compliance with Regulation 47(1)(b) of the SEBI Listing Regulations, 2015**

Please find attached herewith copies of the newspaper publication of Un-audited Financial Results for the quarter and nine months ended December 31, 2019, published in Financial Express and Andhra Prabha on February 12, 2020 for your reference.

Thanking you,

Yours faithfully,

For Neuland Laboratories Limited



**Sarada Bhamidipati**  
Company Secretary



*Encl : As above*

## NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor  
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2019  
(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended 31.12.2019	Quarter Ended 31.12.2018	Nine months Ended 31.12.2019	Nine months Ended 31.12.2018
1	Revenue from operations	20,384.37	17,147.95	57,106.89	49,417.78
2	Net profit for the period before tax	1,567.18	601.25	3,572.45	1,216.68
3	Net profit for the period after tax	1,111.04	469.16	2,550.62	981.10
4	Total comprehensive income for the period	1,085.27	480.86	2,472.15	1,068.94
5	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet	68,556.84	23,739.91	68,556.84	23,739.91
	As at 31.03.2019	As at 31.03.2018	As at 31.03.2019	As at 31.03.2018	
7	Earnings Per Share (of ₹10 each)				
	(In absolute ₹ terms)				
	(a) Basic	8.66	3.66	19.88	7.84
	(b) Diluted	8.66	3.66	19.88	7.84

Note 1: The financial results for the quarter and nine months ended 31 December 2019 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11 February 2020.

Note 2: Key Standalone Financial Information: (Amount in lakhs of ₹)

Particulars	Quarter Ended 31.12.2019	Quarter Ended 31.12.2018	Nine months Ended 31.12.2019	Nine months Ended 31.12.2018
Revenue from operations	20,361.97	17,146.95	57,084.49	49,416.78
Net profit for the period before tax	1,557.46	589.57	3,541.90	1,174.45
Net profit for the period after tax	1,104.26	460.00	2,523.01	941.39

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board  
For Neuland Laboratories Limited  
Dr. D.R.Rao  
Chairman & Managing Director  
(DIN 00107737)

Place: Hyderabad  
Date : 11 February 2020

## NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor  
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2019  
(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended 31.12.2019	Quarter Ended 31.12.2018	Nine months Ended 31.12.2019	Nine months Ended 31.12.2018
1	Revenue from operations	20,384.37	17,147.95	57,106.89	49,417.78
2	Net profit for the period before tax	1,567.18	601.25	3,572.45	1,216.68
3	Net profit for the period after tax	1,111.04	469.16	2,550.62	981.10
4	Total comprehensive income for the period	1,085.27	480.86	2,472.15	1,068.94
5	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet	68,556.84	23,739.91	68,556.84	23,739.91
	As at 31.03.2019	As at 31.03.2018	As at 31.03.2019	As at 31.03.2018	
7	Earnings Per Share (of ₹10 each)				
	(In absolute ₹ terms)				
	(a) Basic	8.66	3.66	19.88	7.84
	(b) Diluted	8.66	3.66	19.88	7.84

Note 1: The financial results for the quarter and nine months ended 31 December 2019 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11 February 2020.

Note 2: Key Standalone Financial Information: (Amount in lakhs of ₹)

Particulars	Quarter Ended 31.12.2019	Quarter Ended 31.12.2018	Nine months Ended 31.12.2019	Nine months Ended 31.12.2018
Revenue from operations	20,361.97	17,146.95	57,084.49	49,416.78
Net profit for the period before tax	1,557.46	589.57	3,541.90	1,174.45
Net profit for the period after tax	1,104.26	460.00	2,523.01	941.39

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board  
For Neuland Laboratories Limited,  
Dr. D.R.Rao  
Chairman & Managing Director  
(DIN 00107737)

Place: Hyderabad  
Date : 11 February 2020